Status:
COMPLETED
AL Amyloidosis and Anti-CD38-Daratunumab
Lead Sponsor:
University of Turin, Italy
Conditions:
Amyloidosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
AL Amyloidosis and anti-CD38
Detailed Description
AL amyloidosis is a systemic disorder characterized by progressive multiorgan failure and premature death. While autologous stem cell transplantation (ASCT) is considered the standard therapy, eligibi...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients affected by AL amyloidosis
- Patients who were ineligible for high dose therapy and bone marrow transplantation due to age and/or frailty score.
- Exclusion criteria:
- \- Diagnosis of AL amyloidosis not biospy proven
Exclusion
Key Trial Info
Start Date :
January 2 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 2 2024
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT06571864
Start Date
January 2 2022
End Date
February 2 2024
Last Update
August 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Giovanni Bosco Hospital
Turin, Piedmont, Italy, 10154